A novel patient-derived meningioma spheroid model as a tool to study and treat epithelial-to-mesenchymal transition (EMT) in meningiomas
dc.contributor.author | van de Weijer, LL | |
dc.contributor.author | Ercolano, E | |
dc.contributor.author | Zhang, T | |
dc.contributor.author | Shah, M | |
dc.contributor.author | Banton, MC | |
dc.contributor.author | Na, J | |
dc.contributor.author | Adams, CL | |
dc.contributor.author | Hilton, D | |
dc.contributor.author | Kurian, KM | |
dc.contributor.author | Hanemann, CO | |
dc.date.accessioned | 2024-01-19T11:44:54Z | |
dc.date.available | 2024-01-19T11:44:54Z | |
dc.date.issued | 2023-12-15 | |
dc.identifier.issn | 2051-5960 | |
dc.identifier.issn | 2051-5960 | |
dc.identifier.other | 198 | |
dc.identifier.uri | https://pearl.plymouth.ac.uk/handle/10026.1/21916 | |
dc.description.abstract |
Meningiomas are the most common intracranial brain tumours. These tumours are heterogeneous and encompass a wide spectrum of clinical aggressivity. Treatment options are limited to surgery and radiotherapy and have a risk of post-operative morbidities and radiation neurotoxicity, reflecting the need for new therapies. Three-dimensional (3D) patient-derived cell culture models have been shown to closely recapitulate in vivo tumour biology, including microenvironmental interactions and have emerged as a robust tool for drug development. Here, we established a novel easy-to-use 3D patient-derived meningioma spheroid model using a scaffold-free approach. Patient-derived meningioma spheroids were characterised and compared to patient tissues and traditional monolayer cultures by histology, genomics, and transcriptomics studies. Patient-derived meningioma spheroids closely recapitulated morphological and molecular features of matched patient tissues, including patient histology, genomic alterations, and components of the immune microenvironment, such as a CD68 + and CD163 + positive macrophage cell population. Comprehensive transcriptomic profiling revealed an increase in epithelial-to-mesenchymal transition (EMT) in meningioma spheroids compared to traditional monolayer cultures, confirming this model as a tool to elucidate EMT in meningioma. Therefore, as proof of concept study, we developed a treatment strategy to target EMT in meningioma. We found that combination therapy using the MER tyrosine kinase (MERTK) inhibitor UNC2025 and the histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) effectively decreased meningioma spheroid viability and proliferation. Furthermore, we demonstrated this combination therapy significantly increased the expression of the epithelial marker E-cadherin and had a repressive effect on WHO grade 2-derived spheroid invasion, which is suggestive of a partial reversal of EMT in meningioma spheroids. | |
dc.format.extent | 198- | |
dc.format.medium | Electronic | |
dc.language | en | |
dc.publisher | Springer Science and Business Media LLC | |
dc.subject | Meningioma | |
dc.subject | Spheroids | |
dc.subject | EMT | |
dc.subject | MERTK | |
dc.subject | HDAC | |
dc.subject | Combination therapy | |
dc.title | A novel patient-derived meningioma spheroid model as a tool to study and treat epithelial-to-mesenchymal transition (EMT) in meningiomas | |
dc.type | journal-article | |
dc.type | Article | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/38102708 | |
plymouth.issue | 1 | |
plymouth.volume | 11 | |
plymouth.publisher-url | http://dx.doi.org/10.1186/s40478-023-01677-9 | |
plymouth.publication-status | Published online | |
plymouth.journal | Acta Neuropathologica Communications | |
dc.identifier.doi | 10.1186/s40478-023-01677-9 | |
plymouth.organisational-group | |Plymouth | |
plymouth.organisational-group | |Plymouth|Research Groups | |
plymouth.organisational-group | |Plymouth|Faculty of Health | |
plymouth.organisational-group | |Plymouth|Research Groups|Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | |Plymouth|Research Groups|Institute of Translational and Stratified Medicine (ITSMED)|CBR | |
plymouth.organisational-group | |Plymouth|REF 2021 Researchers by UoA | |
plymouth.organisational-group | |Plymouth|Users by role | |
plymouth.organisational-group | |Plymouth|Users by role|Academics | |
plymouth.organisational-group | |Plymouth|REF 2021 Researchers by UoA|UoA01 Clinical Medicine | |
plymouth.organisational-group | |Plymouth|Faculty of Health|Peninsula Medical School | |
plymouth.organisational-group | |Plymouth|Users by role|Researchers in ResearchFish submission | |
plymouth.organisational-group | |Plymouth|REF 2028 Researchers by UoA | |
plymouth.organisational-group | |Plymouth|REF 2028 Researchers by UoA|UoA01 Clinical Medicine | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2023-10-23 | |
dc.date.updated | 2024-01-19T11:44:53Z | |
dc.rights.embargodate | 2024-1-27 | |
dc.identifier.eissn | 2051-5960 | |
rioxxterms.versionofrecord | 10.1186/s40478-023-01677-9 |